WallStreetZenWallStreetZen

NASDAQ: PLRX
Pliant Therapeutics Inc Stock

$12.86-0.64 (-4.74%)
Updated Jul 17, 2024
PLRX Price
$12.86
Fair Value Price
$0.84
Market Cap
$775.79M
52 Week Low
$10.29
52 Week High
$20.23
P/E
-4.48x
P/B
1.77x
P/S
3,615.71x
PEG
N/A
Dividend Yield
N/A
Revenue
$248.00k
Earnings
-$170.74M
Gross Margin
100%
Operating Margin
-68,282.66%
Profit Margin
-68,848%
Debt to Equity
0.19
Operating Cash Flow
-$116M
Beta
0.82
Next Earnings
Aug 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

PLRX Overview

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PLRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PLRX ($12.86) is overvalued by 1,436.6% relative to our estimate of its Fair Value price of $0.84 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PLRX ($12.86) is not significantly undervalued (1,436.6%) relative to our estimate of its Fair Value price of $0.84 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PLRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PLRX due diligence checks available for Premium users.

Be the first to know about important PLRX news, forecast changes, insider trades & much more!

PLRX News

Valuation

PLRX fair value

Fair Value of PLRX stock based on Discounted Cash Flow (DCF)
Price
$12.86
Fair Value
$0.84
Overvalued by
1,436.60%
PLRX ($12.86) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PLRX ($12.86) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PLRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PLRX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.48x
Industry
-21.17x
Market
30.24x

PLRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.77x
Industry
6.35x
PLRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PLRX's financial health

Profit margin

Revenue
$0.0
Net Income
-$47.0M
Profit Margin
0%
PLRX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PLRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$521.6M
Liabilities
$84.3M
Debt to equity
0.19
PLRX's short-term assets ($489.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PLRX's short-term assets ($489.90M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PLRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$30.3M
Investing
$59.5M
Financing
$21.8M
PLRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PLRX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
PLRX$775.79M-4.74%-4.48x1.77x
TVTX$783.37M+0.68%-4.83x10.58x
PRME$754.99M-6.12%-2.89x3.10x
MESO$748.92M-3.78%-8.09x1.47x
OLMA$807.13M-1.70%-7.18x3.42x

Pliant Therapeutics Stock FAQ

What is Pliant Therapeutics's quote symbol?

(NASDAQ: PLRX) Pliant Therapeutics trades on the NASDAQ under the ticker symbol PLRX. Pliant Therapeutics stock quotes can also be displayed as NASDAQ: PLRX.

If you're new to stock investing, here's how to buy Pliant Therapeutics stock.

What is the 52 week high and low for Pliant Therapeutics (NASDAQ: PLRX)?

(NASDAQ: PLRX) Pliant Therapeutics's 52-week high was $20.23, and its 52-week low was $10.29. It is currently -36.43% from its 52-week high and 24.98% from its 52-week low.

How much is Pliant Therapeutics stock worth today?

(NASDAQ: PLRX) Pliant Therapeutics currently has 60,325,832 outstanding shares. With Pliant Therapeutics stock trading at $12.86 per share, the total value of Pliant Therapeutics stock (market capitalization) is $775.79M.

Pliant Therapeutics stock was originally listed at a price of $21.30 in Jun 3, 2020. If you had invested in Pliant Therapeutics stock at $21.30, your return over the last 4 years would have been -39.62%, for an annualized return of -11.85% (not including any dividends or dividend reinvestments).

How much is Pliant Therapeutics's stock price per share?

(NASDAQ: PLRX) Pliant Therapeutics stock price per share is $12.86 today (as of Jul 17, 2024).

What is Pliant Therapeutics's Market Cap?

(NASDAQ: PLRX) Pliant Therapeutics's market cap is $775.79M, as of Jul 18, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Pliant Therapeutics's market cap is calculated by multiplying PLRX's current stock price of $12.86 by PLRX's total outstanding shares of 60,325,832.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.